GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » EBIT

Hansoh Pharmaceutical Group Co (HKSE:03692) EBIT : HK$4,192 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co EBIT?

Hansoh Pharmaceutical Group Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$2,518 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,192 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hansoh Pharmaceutical Group Co's annualized ROC % for the quarter that ended in Dec. 2023 was 30.53%. Hansoh Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 102.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hansoh Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.51%.


Hansoh Pharmaceutical Group Co EBIT Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co EBIT Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 3,339.42 3,674.78 4,105.52 3,357.48 4,192.27

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,178.00 1,802.58 1,640.22 1,674.16 2,518.11

Competitive Comparison of Hansoh Pharmaceutical Group Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's EV-to-EBIT falls into.



Hansoh Pharmaceutical Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4,192 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co  (HKSE:03692) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hansoh Pharmaceutical Group Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=3838.25 * ( 1 - 12.25% )/( (11193.636 + 10872.221)/ 2 )
=3368.064375/11032.9285
=30.53 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34937.883 - 1501.995 - ( 25743.453 - max(0, 8111.386 - 30353.638+25743.453))
=11193.636

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36137.447 - 1179.714 - ( 27188.134 - max(0, 7506.439 - 31591.951+27188.134))
=10872.221

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Hansoh Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5036.224/( ( (3699.534 + max(1064.428, 0)) + (3602.525 + max(1470.501, 0)) )/ 2 )
=5036.224/( ( 4763.962 + 5073.026 )/ 2 )
=5036.224/4918.494
=102.39 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3618.684 + 656.688 + 0) - (1501.995 + 0 + 1708.949)
=1064.428

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3510.629 + 629.778 + 243.444) - (1179.714 + 0 + 1733.636)
=1470.501

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hansoh Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=4192.275/76096.440
=5.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co EBIT Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Executives
Cen Junda 2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited 2301 Trustee
Jqc Holding Limited 2201 Interest of corporation controlled by you
Jqc International Limited 2201 Interest of corporation controlled by you
Sun Yuan 2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited 2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd. 2101 Beneficial owner
Sunrise Investment Advisors Limited 2201 Interest of corporation controlled by you
Zhong Huijuan 2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd. 2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines